TD Cowen initiated coverage of Medline (MDLN) with a Buy rating and $46 price target The firm believes Medline, as the leading medical-surgical distributor and manufacturer, can continue to take market share, see margin expansion from conversion to branded products, and grow from entering new markets. Tariffs are a “large but manageable risk” for the company, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline initiated with a Buy at BTIG
- Medline initiated with an Outperform at Mizuho
- Medline: Durable Moat, Secular Tailwinds, and Attractive Valuation Support Buy Rating
- Medline: Durable Growth, Expanding Market Share, and Margin Upside Support Buy Rating and $46 Target
- Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward